A new treatment using gut microbiome to help patients with severe lung injury from viruses

Who could benefit from this research

What this research studies

This research investigates a novel therapeutic approach for treating acute respiratory distress syndrome (ARDS) caused by viral infections. It focuses on the role of neutrophils, a type of immune cell, in the inflammatory response associated with ARDS. By leveraging the gut microbiome, the study aims to modulate immune responses and reduce inflammation, potentially improving patient outcomes. The approach is designed to be rapid and broadly applicable, addressing the urgent need for effective treatments in the context of viral pandemics.

Why it matters

Where this research is happening

• Rise Therapeutics, LLC
  Rockville, United States Active

Researchers

• Principal investigator: Furlan Freguia, Christian — Rise Therapeutics, LLC
• Study coordinator: Furlan Freguia, Christian

Related research

Other NIH-funded projects on the same topics.

• Resilience endotypes and early ARDS detection using biomarkers and AI

  A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.

  NIH research Duke University · Durham, United States · NIH-11416345

• Understanding immune checkpoints in acute respiratory distress syndrome

  This study is looking at how certain immune pathways might affect people with acute respiratory distress syndrome (ARDS) to help create better treatment options and improve care for patients who need long-term breathing support.

  NIH research Benaroya Research Inst at Virginia Mason · Seattle, United States · NIH-10871697

• Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data

  This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11432547

• PAR1’s role in lung lymphatics and a new therapy approach for ARDS

  This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.

  NIH research Weill Medical Coll of Cornell Univ · New York, United States · NIH-11412416

• Dead space and inhaled nitric oxide in pediatric ARDS

  This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.

  NIH research Children's Hospital of Los Angeles · Los Angeles, United States · NIH-11411416

• Immune, hormone, and muscle energy links to recovery after ARDS

  This project looks at why some ARDS survivors have ongoing weakness and how immune, hormone, and muscle energy factors might influence recovery.</n>

  NIH research Columbia University Health Sciences · New York, United States · NIH-11402596

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.